Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAAT3 | P53816 | 1/20 | 0.52 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.52 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.52 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | LIPE | Q05469 | 10/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3549808 | 0.95 | PLAAT3 (0.47) | PLAAT3PLAAT5PLAAT2PLAAT4LMNA | |
| SCHEMBL8410599 | 0.90 | LMNA (0.48) | PLAAT3PLAAT5PLAAT2PLAAT4LMNA | |
| SCHEMBL8330868 | 0.80 | EPHX2 (0.46) | LMNA | |
| SCHEMBL15684814 | 0.76 | LMNA (0.48) | PLAAT3PLAAT5PLAAT2PLAAT4LMNA | |
| SCHEMBL5261641 | 0.75 | SCN9A (0.42) | PLAAT3PLAAT5PLAAT2PLAAT4LMNA | |
| SCHEMBL15684950 | 0.74 | PLAAT3 (0.47) | PLAAT3PLAAT5PLAAT2PLAAT4LMNA | |
| SCHEMBL8410794 | 0.74 | LMNA (0.47) | PLAAT3PLAAT5PLAAT2PLAAT4LMNA | |
| SCHEMBL8412024 | 0.73 | L3MBTL1 (0.47) | LMNARAB9A | |
| SCHEMBL15684905 | 0.72 | LMNA (0.47) | PLAAT3PLAAT5PLAAT2PLAAT4LMNA | |
| SCHEMBL15684930 | 0.72 | LMNA (0.45) | PLAAT3PLAAT5PLAAT2PLAAT4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652041-B2 | 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | claimed |
| EP-1856053-A1 | CINNAMIDE AND HYDROCINNAMIDE DERIVATIVES WITH RAF-KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-11-21 | — | — | EP | claimed |
| WO-2006076706-A1 | CINNAMIDE AND HYDROCINNAMIDE DERIVATIVES WITH RAF-KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| US-20060160803-A1 | Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | claimed |
| US-7652041-B2 | 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20060160803-A1 | Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160803-A1 | Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity | MAP3K21, HIPK4, MAP3K20 | PLAAT3 1325/4885PLAAT5 1888/4885PLAAT2 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.